OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104
NANTES, France, Feb. 17, 2022 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)…
NVIDIA Vera BlueField-4 STX Brings Agentic AI Storage Processing With In-Silicon Security
How to Manage Overseas Expenses Without Disrupting Your Monthly Budget
Unitree Robotics IPO Enters Listing Review Stage; Total Value of Funds Held by Shoucheng Expected to Exceed RMB 8 Billion
Malaysia-Based ONE COMPANY Foundation Unveils ONE WALLET, a Keyless Telegram-Native Wallet on TON